These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 24517248)

  • 21. Clinical and pharmacologic evaluation of two dosing schedules of indotecan (LMP400), a novel indenoisoquinoline, in patients with advanced solid tumors.
    Kummar S; Chen A; Gutierrez M; Pfister TD; Wang L; Redon C; Bonner WM; Yutzy W; Zhang Y; Kinders RJ; Ji J; Allen D; Covey JM; Eiseman JL; Holleran JL; Beumer JH; Rubinstein L; Collins J; Tomaszewski J; Parchment R; Pommier Y; Doroshow JH
    Cancer Chemother Pharmacol; 2016 Jul; 78(1):73-81. PubMed ID: 27169793
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synthesis of nitrated indenoisoquinolines as topoisomerase I inhibitors.
    Morrell A; Antony S; Kohlhagen G; Pommier Y; Cushman M
    Bioorg Med Chem Lett; 2004 Jul; 14(14):3659-63. PubMed ID: 15203138
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synthesis and evaluation of indenoisoquinoline topoisomerase I inhibitors substituted with nitrogen heterocycles.
    Nagarajan M; Morrell A; Ioanoviciu A; Antony S; Kohlhagen G; Agama K; Hollingshead M; Pommier Y; Cushman M
    J Med Chem; 2006 Oct; 49(21):6283-9. PubMed ID: 17034134
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Design, synthesis, and biological evaluation of O-2-modified indenoisoquinolines as dual topoisomerase I-tyrosyl-DNA phosphodiesterase I inhibitors.
    Lv PC; Agama K; Marchand C; Pommier Y; Cushman M
    J Med Chem; 2014 May; 57(10):4324-36. PubMed ID: 24800942
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Investigation of the Structure-Activity Relationships of Aza-A-Ring Indenoisoquinoline Topoisomerase I Poisons.
    Beck DE; Reddy PV; Lv W; Abdelmalak M; Tender GS; Lopez S; Agama K; Marchand C; Pommier Y; Cushman M
    J Med Chem; 2016 Apr; 59(8):3840-53. PubMed ID: 27070999
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The structure-activity relationships of A-ring-substituted aromathecin topoisomerase I inhibitors strongly support a camptothecin-like binding mode.
    Cinelli MA; Morrell AE; Dexheimer TS; Agama K; Agrawal S; Pommier Y; Cushman M
    Bioorg Med Chem; 2010 Aug; 18(15):5535-52. PubMed ID: 20630766
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synthesis and anticancer activity of simplified indenoisoquinoline topoisomerase I inhibitors lacking substituents on the aromatic rings.
    Nagarajan M; Morrell A; Fort BC; Meckley MR; Antony S; Kohlhagen G; Pommier Y; Cushman M
    J Med Chem; 2004 Nov; 47(23):5651-61. PubMed ID: 15509164
    [TBL] [Abstract][Full Text] [Related]  

  • 28. BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers.
    Coussy F; El-Botty R; Château-Joubert S; Dahmani A; Montaudon E; Leboucher S; Morisset L; Painsec P; Sourd L; Huguet L; Nemati F; Servely JL; Larcher T; Vacher S; Briaux A; Reyes C; La Rosa P; Lucotte G; Popova T; Foidart P; Sounni NE; Noel A; Decaudin D; Fuhrmann L; Salomon A; Reyal F; Mueller C; Ter Brugge P; Jonkers J; Poupon MF; Stern MH; Bièche I; Pommier Y; Marangoni E
    Sci Transl Med; 2020 Feb; 12(531):. PubMed ID: 32075943
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synthesis and biological evaluation of bisindenoisoquinolines as topoisomerase I inhibitors.
    Nagarajan M; Morrell A; Antony S; Kohlhagen G; Agama K; Pommier Y; Ragazzon PA; Garbett NC; Chaires JB; Hollingshead M; Cushman M
    J Med Chem; 2006 Aug; 49(17):5129-40. PubMed ID: 16913702
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Quantitative structure-activity relationship studies on indenoisoquinoline topoisomerase I inhibitors as anticancer agents in human renal cell carcinoma cell line SN12C.
    Zhi Y; Yang J; Tian S; Yuan F; Liu Y; Zhang Y; Sun P; Song B; Chen Z
    Int J Mol Sci; 2012; 13(5):6009-6025. PubMed ID: 22754346
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Design, synthesis and biological evaluation of 3-substituted indenoisoquinoline derivatives as topoisomerase I inhibitors.
    Zhao Q; Xu X; Xie Z; Liu X; You Q; Guo Q; Zhong Y; Li Z
    Bioorg Med Chem Lett; 2016 Feb; 26(3):1068-1072. PubMed ID: 26725027
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Optimization of the indenone ring of indenoisoquinoline topoisomerase I inhibitors.
    Morrell A; Placzek M; Parmley S; Grella B; Antony S; Pommier Y; Cushman M
    J Med Chem; 2007 Sep; 50(18):4388-404. PubMed ID: 17676830
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting Topoisomerase I in the Era of Precision Medicine.
    Thomas A; Pommier Y
    Clin Cancer Res; 2019 Nov; 25(22):6581-6589. PubMed ID: 31227499
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A systematic study of nitrated indenoisoquinolines reveals a potent topoisomerase I inhibitor.
    Morrell A; Antony S; Kohlhagen G; Pommier Y; Cushman M
    J Med Chem; 2006 Dec; 49(26):7740-53. PubMed ID: 17181156
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synthesis of new dihydroindeno[1,2-c]isoquinoline and indenoisoquinolinium chloride topoisomerase I inhibitors having high in vivo anticancer activity in the hollow fiber animal model.
    Jayaraman M; Fox BM; Hollingshead M; Kohlhagen G; Pommier Y; Cushman M
    J Med Chem; 2002 Jan; 45(1):242-9. PubMed ID: 11754595
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Design, synthesis, and evaluation of dibenzo[c,h][1,6]naphthyridines as topoisomerase I inhibitors and potential anticancer agents.
    Kiselev E; Dexheimer TS; Pommier Y; Cushman M
    J Med Chem; 2010 Dec; 53(24):8716-26. PubMed ID: 21090809
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Indenoisoquinoline Topoisomerase Inhibitors Strongly Bind and Stabilize the
    Wang KB; Elsayed MSA; Wu G; Deng N; Cushman M; Yang D
    J Am Chem Soc; 2019 Jul; 141(28):11059-11070. PubMed ID: 31283877
    [No Abstract]   [Full Text] [Related]  

  • 38. Investigation of the lactam side chain length necessary for optimal indenoisoquinoline topoisomerase I inhibition and cytotoxicity in human cancer cell cultures.
    Morrell A; Placzek MS; Steffen JD; Antony S; Agama K; Pommier Y; Cushman M
    J Med Chem; 2007 May; 50(9):2040-8. PubMed ID: 17402722
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel indenoisoquinolines NSC 725776 and NSC 724998 produce persistent topoisomerase I cleavage complexes and overcome multidrug resistance.
    Antony S; Agama KK; Miao ZH; Takagi K; Wright MH; Robles AI; Varticovski L; Nagarajan M; Morrell A; Cushman M; Pommier Y
    Cancer Res; 2007 Nov; 67(21):10397-405. PubMed ID: 17974983
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 3-Arylisoquinolines as novel topoisomerase I inhibitors.
    Khadka DB; Cho WJ
    Bioorg Med Chem; 2011 Jan; 19(2):724-34. PubMed ID: 21095131
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.